palmarumycin cp(1)

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

palmarumycin CP(1): a type of spirobisnaphthalene, which contain two naphthalene-derived c10 units bridged through a spiroketal linkage with two oxygen bridges; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	196959
CHEMBL ID	88230
SCHEMBL ID	17250054
MeSH ID	M0382292

Synonyms (11)

Synonym
CHEMBL88230 ,
palmarumycin cp(1)
159933-90-1
palmarumycin cp1
DTXSID80166774
SCHEMBL17250054
bdbm50218814
8'-hydroxyspiro[2,4-dioxatricyclo[7.3.1.05,13]trideca-1(12),5,7,9(13),10-pentaene-3,4'-naphthalene]-1'-one
palmarumycin derivative 1
EN300-26619641
5-hydroxy-4h-2',4'-dioxaspiro[naphthalene-1,3'-tricyclo[7.3.1.0,5,13]tridecane]-1'(13'),5',7',9',11'-pentaen-4-one

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Thioredoxin reductase 1, cytoplasmic	Homo sapiens (human)	IC50 (µMol)	6.1750	0.0432	2.2655	5.0000	AID213103; AID213244
Thioredoxin reductase 3	Homo sapiens (human)	IC50 (µMol)	6.1750	0.3500	3.1167	5.0000	AID213103; AID213244
Thioredoxin reductase 2, mitochondrial	Homo sapiens (human)	IC50 (µMol)	6.1750	0.3500	3.1167	5.0000	AID213103; AID213244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (11)

Process	via Protein(s)	Taxonomy
mesoderm formation	Thioredoxin reductase 1, cytoplasmic	Homo sapiens (human)
signal transduction	Thioredoxin reductase 1, cytoplasmic	Homo sapiens (human)
cell population proliferation	Thioredoxin reductase 1, cytoplasmic	Homo sapiens (human)
cellular oxidant detoxification	Thioredoxin reductase 1, cytoplasmic	Homo sapiens (human)
cell redox homeostasis	Thioredoxin reductase 1, cytoplasmic	Homo sapiens (human)
spermatogenesis	Thioredoxin reductase 3	Homo sapiens (human)
cell differentiation	Thioredoxin reductase 3	Homo sapiens (human)
cell redox homeostasis	Thioredoxin reductase 3	Homo sapiens (human)
cellular oxidant detoxification	Thioredoxin reductase 3	Homo sapiens (human)
response to oxygen radical	Thioredoxin reductase 2, mitochondrial	Homo sapiens (human)
response to xenobiotic stimulus	Thioredoxin reductase 2, mitochondrial	Homo sapiens (human)
response to selenium ion	Thioredoxin reductase 2, mitochondrial	Homo sapiens (human)
cell redox homeostasis	Thioredoxin reductase 2, mitochondrial	Homo sapiens (human)
response to hyperoxia	Thioredoxin reductase 2, mitochondrial	Homo sapiens (human)
cellular oxidant detoxification	Thioredoxin reductase 2, mitochondrial	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Process	via Protein(s)	Taxonomy
thioredoxin-disulfide reductase (NADPH) activity	Thioredoxin reductase 1, cytoplasmic	Homo sapiens (human)
protein binding	Thioredoxin reductase 1, cytoplasmic	Homo sapiens (human)
identical protein binding	Thioredoxin reductase 1, cytoplasmic	Homo sapiens (human)
NADPH peroxidase activity	Thioredoxin reductase 1, cytoplasmic	Homo sapiens (human)
FAD binding	Thioredoxin reductase 1, cytoplasmic	Homo sapiens (human)
thioredoxin-disulfide reductase (NADPH) activity	Thioredoxin reductase 3	Homo sapiens (human)
flavin adenine dinucleotide binding	Thioredoxin reductase 3	Homo sapiens (human)
thioredoxin-disulfide reductase (NADPH) activity	Thioredoxin reductase 2, mitochondrial	Homo sapiens (human)
protein binding	Thioredoxin reductase 2, mitochondrial	Homo sapiens (human)
protein homodimerization activity	Thioredoxin reductase 2, mitochondrial	Homo sapiens (human)
protein-containing complex binding	Thioredoxin reductase 2, mitochondrial	Homo sapiens (human)
flavin adenine dinucleotide binding	Thioredoxin reductase 2, mitochondrial	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Process	via Protein(s)	Taxonomy
fibrillar center	Thioredoxin reductase 1, cytoplasmic	Homo sapiens (human)
nucleoplasm	Thioredoxin reductase 1, cytoplasmic	Homo sapiens (human)
cytosol	Thioredoxin reductase 1, cytoplasmic	Homo sapiens (human)
extracellular exosome	Thioredoxin reductase 1, cytoplasmic	Homo sapiens (human)
mitochondrion	Thioredoxin reductase 1, cytoplasmic	Homo sapiens (human)
cytosol	Thioredoxin reductase 1, cytoplasmic	Homo sapiens (human)
cytoplasm	Thioredoxin reductase 1, cytoplasmic	Homo sapiens (human)
nucleoplasm	Thioredoxin reductase 3	Homo sapiens (human)
endoplasmic reticulum	Thioredoxin reductase 3	Homo sapiens (human)
cytosol	Thioredoxin reductase 3	Homo sapiens (human)
mitochondrion	Thioredoxin reductase 3	Homo sapiens (human)
cytoplasm	Thioredoxin reductase 3	Homo sapiens (human)
cytosol	Thioredoxin reductase 3	Homo sapiens (human)
mitochondrion	Thioredoxin reductase 2, mitochondrial	Homo sapiens (human)
mitochondrial matrix	Thioredoxin reductase 2, mitochondrial	Homo sapiens (human)
cytosol	Thioredoxin reductase 2, mitochondrial	Homo sapiens (human)
axon	Thioredoxin reductase 2, mitochondrial	Homo sapiens (human)
dendrite	Thioredoxin reductase 2, mitochondrial	Homo sapiens (human)
neuronal cell body	Thioredoxin reductase 2, mitochondrial	Homo sapiens (human)
cytoplasm	Thioredoxin reductase 2, mitochondrial	Homo sapiens (human)
mitochondrion	Thioredoxin reductase 2, mitochondrial	Homo sapiens (human)
cytosol	Thioredoxin reductase 2, mitochondrial	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (5)

Assay ID	Title	Year	Journal	Article
AID101815	Ability to inhibit the growth of MDA-MB-231 cell line	2001	Bioorganic & medicinal chemistry letters, Oct-08, Volume: 11, Issue:19	New inhibitors of the thioredoxin-thioredoxin reductase system based on a naphthoquinone spiroketal natural product lead.
AID103912	Ability to inhibit the growth of MCF-7 cell line	2001	Bioorganic & medicinal chemistry letters, Oct-08, Volume: 11, Issue:19	New inhibitors of the thioredoxin-thioredoxin reductase system based on a naphthoquinone spiroketal natural product lead.
AID213244	Inhibition of thioredoxin-1/thioredoxin reductase system	2001	Bioorganic & medicinal chemistry letters, Oct-08, Volume: 11, Issue:19	New inhibitors of the thioredoxin-thioredoxin reductase system based on a naphthoquinone spiroketal natural product lead.
AID213103	Inhibition of thioredoxin reductase	2001	Bioorganic & medicinal chemistry letters, Oct-08, Volume: 11, Issue:19	New inhibitors of the thioredoxin-thioredoxin reductase system based on a naphthoquinone spiroketal natural product lead.
AID1265153	Cytotoxicity against human CHP100 cells after 24 hrs by MTT assay	2015	Journal of natural products, Nov-25, Volume: 78, Issue:11	Anteaglonialides A-F and Palmarumycins CE(1)-CE(3) from Anteaglonium sp. FL0768, a Fungal Endophyte of the Spikemoss Selaginella arenicola.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	7 (87.50)	29.6817
2010's	1 (12.50)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.06

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.06 (24.57)
Research Supply Index	2.20 (2.92)
Research Growth Index	4.26 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.06)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (12.50%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	7 (87.50%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
glycine [no description available]	2.03	1	alpha-amino acid; amino acid zwitterion; proteinogenic amino acid; serine family amino acid	EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor; fundamental metabolite; hepatoprotective agent; micronutrient; neurotransmitter; NMDA receptor agonist; nutraceutical
colchicine (S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.	2	1	alkaloid; colchicine	anti-inflammatory agent; gout suppressant; mutagen
triazoles Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.	3.12	1	1,2,3-triazole
naphthoquinones Naphthoquinones: Naphthalene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.	2	1
palmarumycin cp2 palmarumycin CP2: a type of spirobisnaphthalene, which contain two naphthalene-derived c10 units bridged through a spiroketal linkage with two oxygen bridges; structure in first source	2.01	1
diepoxin sigma diepoxin sigma: structure in first source	2	1

Condition	Relationship Strength	Studies
Benign Neoplasms [description not available]	3.35	2
Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.	2.94	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	3.35	2
Breast Cancer [description not available]	2	1
Breast Neoplasms Tumors or cancer of the human BREAST.	2	1

chemdatabank.com